Gaurav Premani, CFA
Biotechnology · Critical Metals · Mining · Pharmaceuticals · Web3 · Healthcare
Gaurav Premani, CFA, is a Partner at Alliance Equity Research, where he focuses on equity research, financial modeling, valuation, and company analysis across public markets. His research spans multiple industries and geographies, with particular experience in healthcare and pharmaceutical businesses and a strong focus on translating business models, operating drivers, and industry dynamics into detailed financial forecasts and valuation frameworks. His work combines fundamental company research, industry analysis, and financial modeling to assess the underlying economics of a business and the financial implications of company and sector developments. He is a CFA charterholder with an academic background in finance.
Research Reports
Authored Insights
Biotechnology & HealthcareAstraZeneca’s $2 Billion Summit Investment Is More Than Validation for Ivonescimab
AstraZeneca is investing $2 billion in Summit Therapeutics at an effective $18.36 per share while leaving ivonescimab’s commercial rights with Summit. The transaction removes a major financing constraint ahead of a November FDA decision, but it also highlights why the economics of strategic equity can differ materially from a conventional licensing deal or acquisition.
Biotechnology & HealthcareNeuroSense’s PrimeC Has Built a Stronger ALS Data Package, but Financing Is Now the Critical Variable
NeuroSense Therapeutics is targeting a Canadian filing for PrimeC in December while exploring a potentially smaller U.S. pivotal program and an accelerated-approval pathway. The clinical dataset has strengthened materially, but with only $0.23 million of cash reported at June 30, the investment case increasingly depends on whether the company can convert its regulatory progress into financing, partnership support, or a more capital-efficient route to approval.
Biotechnology & HealthcareMirum’s Atebrioz Approval Shows Why a Missed Primary Endpoint Does Not Always End a Drug Program
FDA approved Atebrioz for fibrodysplasia ossificans progressiva after a 63-patient trial in which a closely watched lesion-incidence endpoint failed to reach conventional statistical significance. The approval highlights the importance of effect size, endpoint selection and totality of evidence, but for Mirum the commercial question may be harder than the regulatory one.
Market CommentaryAI Gold Rush: Inside the Multi-Trillion-Dollar AI Arms Race With No Clear Payoff (Yet)
With tech giants pouring billions into chips, data centers, and power grids despite unclear returns. Is the payoff coming, or is this a high-stakes gamble?